The sequential gross margin improvement from 34.1% in Q4 2025 to 45.4% in Q2 2026 suggests that volume recovery is beginning to absorb fixed manufacturing overhead, but the persistent negative operating margin implies that R&D and SG&A spending, which have remained stable near $59M per quarter, are still not fully covered. The gap between gross and operating margin of over 45 percentage points highlights the high fixed-cost structure and the need for further revenue growth to achieve sustainable profitability. Investors should monitor whether the 38% YoY revenue surge can translate into operating leverage, as the Q2 2026 operating profit of $292K is marginal and could reverse if demand softens.

The reduction in DSO from 101 days in Q1 2024 to 68 days in Q2 2026 suggests that Cohu is collecting receivables more quickly, possibly due to improved customer payment terms or a shift in revenue mix toward consumables. DIO also declined from 237 days to 152 days over the same period, indicating better inventory management, though the absolute level remains high, reflecting the specialized nature of test handlers and interface products. The CCC improvement is a positive sign, but the still-elevated 158 days underscores the capital intensity of the business and the importance of working capital swings, which have been the primary driver of operating cash flow volatility.

The strategic increase in debt, likely to fund expansion or acquisitions, has shifted Cohu from a near-zero leverage position to a more conventional capital structure, but the interest coverage ratio of 2.23x in Q2 2026 indicates that operating income is barely sufficient to cover interest expenses. Given the cyclicality of the semiconductor equipment industry, this leverage could become a strain if the recovery stalls, as evidenced by the negative interest coverage in prior quarters when operating income was deeply negative. The company's ample liquidity, with a current ratio of 5.74 and cash of $219.6M, provides a buffer, but investors should monitor whether the debt-funded expansion generates sufficient returns to justify the increased financial risk.

The high current and quick ratios, which have remained above 4.0 throughout the past ten quarters, suggest that Cohu has a substantial cushion of cash and receivables to cover short-term obligations, even during periods of negative operating cash flow. This liquidity is critical given the cyclical nature of the business, where OSAT customers can delay capital expenditures, and it provides flexibility to maintain R&D and manufacturing capabilities through troughs. However, the reliance on working capital releases for cash generation, as seen in the volatile FCF margins, implies that the liquidity position could deteriorate if inventory builds up again or receivables collection slows, so the trend in CCC should be closely watched.

Relative to its peer group, Cohu's valuation multiples appear elevated on a forward basis, but this reflects the market's expectation of a cyclical earnings rebound rather than current profitability, which is negative. The P/B of 2.90 is lower than FormFactor's 8.23 and Onto Innovation's 6.30, indicating that investors are assigning less value to Cohu's asset base, possibly due to its lower return on equity and the intangible-heavy balance sheet from the Xcerra acquisition. The negative net margin of -16.4% TTM contrasts sharply with peers like Axcelis at 14.3%, highlighting that Cohu is still in the early stages of a recovery, and the valuation gap may narrow if the margin expansion proves sustainable.